Skip to main content
SpringerLink
Log in

Geschichte der Gonadotropintherapie

  • Chapter
Das Deutsche IVF-Register 1996–2006

Auszug

Wenngleich es heute als selbstverständlich gilt, dass die Gonadotropintherapie eine wichtige Komponente im alltäglichen Management der Sterilität darstellt, waren bis heute doch erhebliche Forschungsanstrengungen und Entdeckungen erforderlich. Der Beginn dieses Prozesses ist in den frühen Versuchen zu finden, aus Tiermaterial, menschlichen Leichen und menschlichem Urin, Zubereitungen zu extrahieren und zu reinigen. Daraus entwickelte sich dann die heutige Produktion mittels rekombinanter DNA-Technologie. Heute werden hoch entwickelte Zellkulturtechniken verwendet, um aus Ovarzellen des chinesischen Hamsters (CHO) rekombinante Moleküle zu erzeugen. Dieser konstante Entwicklungsprozess stand immer unter der Notwendigkeit, sichere, reine und effektive Gonadotropinpräparate herzustellen, sowohl für die Therapie selbst als auch für die unkomplizierte Anwendung durch den Patienten.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Agrawal R, West C, Conway GS, Page ML and Jacobs HS (1997) Pregnancy after treatment with three recombinant gonadotropins. Lancet 349,29–30.

    Article  PubMed  CAS  Google Scholar 

  2. Ascheim S, Zondek B (1927) Hypophysenvorderlappen hormone und ovarialhormone im Harn von Schwangeren. Klin Wochenschr 6,13–21.

    Article  Google Scholar 

  3. Aschner B (1912) über die Beziehung zwischen Hypophysis und Genitale. Arch Gyn 97,200–227.

    Article  Google Scholar 

  4. Bachman C (1935) Immunologic studies of anti-gonadotropic sera. Proc Soc Exp Biol Med 32,851–854.

    CAS  Google Scholar 

  5. Beckers NG, Macklon NS, Devroey P, Platteau P, Boerrigter PJ, Fauser BC (2003) First live birth after ovarian stimulation using a chimeric longacting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for in vitro fertilization. Fertil Steril 79(3),621–623.

    Article  PubMed  Google Scholar 

  6. Bettendorf G (1963) Human hypophyseal gonadotropin in hypophysectomised women. Int J Fertil 45,799–809.

    Google Scholar 

  7. Boime I, Keene J, Galway AB, Fares FM (1990) Expression of recombinant human FSH, LH and CG in mammalian cells, a structure-function model for therapeutic drug design. Semin Reprod Endocrinol 10,45–50.

    Google Scholar 

  8. Borth R, Lunenfeld B, de Watteville H (1954) Activité gonadotrope d’un extrait d’urines de femmes en menopause. Experientia 10,266–270.

    Article  PubMed  CAS  Google Scholar 

  9. Bouloux PM, Handelsman DJ, Jockenhovel F et al. (2001) First human exposure to FSH-CPT in hypogonadotrophic hypogonadal males. Hum Reprod 16,1592–1597.

    Article  PubMed  CAS  Google Scholar 

  10. Cochius JI, Mack K, Burns RJ (1990) Creutzfeld-Jakob disease in a recipient human pituitary derived gonadotrophin. Aust NZ J Med 20,592–596.

    CAS  Google Scholar 

  11. Cole HH, Hart GH (1930) The potency of blood serum of mares in progressive stages of pregnancy in affecting the sexual maturity of the immature rat. Am J Physiol 93,57.

    CAS  Google Scholar 

  12. Crowe SJ, Cushing H, Homans J (1910) Experimental hypophysectomy. Bull Johns Hopkins Hosp 21,127–167.

    Google Scholar 

  13. Daume E (1970) Comparison of HMG p HCG and sheep pituitary Gonadotropin ßHCG for the induction of ovulation in the human. In Bettendorf G and Insler V (eds) Clinical Application of Human Gonadotropins. Georg Thieme Verlag, Stuttgart, pp 103–112.

    Google Scholar 

  14. Daya S, Ledger W, Auray JP, Duru G, Silverberg K, Wikland M, Bouzayen R, Howles CM, Beresniak A (2001) Cost-effectiveness modelling of recombinant FSH versus urinary FSH in assisted reproduction techniques in the UK. Hum Reprod 16,2563–2569.

    Article  PubMed  CAS  Google Scholar 

  15. Devroey P, Van Steirteghem A, Mannaerts B, Coelingh Bennink H (1992) Successful in-vitro fertilization and embryo transfer after treatment with recombinant human FSH. Lancet 339,1170–1171.

    Article  PubMed  CAS  Google Scholar 

  16. Donderwinkel PFJ, Schoot DC, Coelingh I, Bennink HJT, Fauser CJM (2002) Pregnancy after induction of ovulation with recombinant human FSH in polycystic ovary syndrome. Lancet 340,983.

    Article  Google Scholar 

  17. Donini P, Montezemolo R (1949) Rassegna di Clinica, Terapia e Scienze Affini. In A publication of the Biologic Laboratories of the Instituto Serono, 48. pp 3–28.

    Google Scholar 

  18. Donini P, Puzzuoli D, Montezemolo R (1964) Purification of Gonadotropin from human menopausal urine. Acta Endocrinol 45,329–329.

    PubMed  CAS  Google Scholar 

  19. Donini P, Puzzuoli D, D’Alessio I, Lunenfeld B, Eshkol A, Parlow AF (1966) Purification and separation of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from human postmenopausal gonadotrophin (HMG). Acta Endocrinol 52,169–185.

    PubMed  CAS  Google Scholar 

  20. Driebergen R, Basset R, Baer G et al. (2002) Improvements in quantification of rhFSH activity: SE-HPLC vs the in vitro rat bioassay. Hum Reprod (Abstract book) 17, 163 (p480).

    Google Scholar 

  21. Duijkers IJ, Klipping C, Boerrigter PJ et al. (2002) Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. Hum Reprod 17,1987–1993.

    Article  PubMed  CAS  Google Scholar 

  22. Dumble LD, Klein RD (1992) Creutzfeld-Jakob disease legacy for Australian women treated with human pituitary gonadotropins. Lancet 330,848.

    Google Scholar 

  23. Eshkol A, Lunenfeld B (1967) Purification and separation of follicle stimulating hormone (FSH) and luteinizing hormone (LH) from human menopausal gonadotrophin (HMG) Part III. Acta Endocrinologica 54,919.

    Google Scholar 

  24. Fares FA, Suganuma N, Mishimori K, LaPolt P, Hsue AJ, Boime W (1992) Design of long acting follitropin agonist by fusing the C terminal sequence of chorionic gonadotropin b subunit to the folitropin b subunit. Proc Natl Acad Sci USA 89,4304–4308.

    Article  PubMed  CAS  Google Scholar 

  25. Gabizon R (2003) Abnormal PrP isoforms in urine. In XVth Congress of the International Society of Neuropathology. Torino, Italy, September 2003.

    Google Scholar 

  26. Gemzell CA, Diczfalusy E, Tillinger G (1958) Clinical effect of human pituitary follicle stimulating hormone (FSH). J Clin Endcrinol Metab 18,1333.

    CAS  Google Scholar 

  27. Germond M, Dessole S, Senn A et al. (1992) Successful in-vitro fertilization and embryo transfer after treatment with recombinant human FSH. Lancet 339,1170.

    Article  PubMed  CAS  Google Scholar 

  28. Groot-Wassink K, Blawert H (1973) Vergleichende Untersuchungen zur Ovulationsauslösung mit Folistiman und Pergonal. Zbl Gynek 9,1019–1024.

    Google Scholar 

  29. Hamblen EC (1933) Human ovarian responses to extracts of pregnancy urine-preliminary report. Virginia M Monthly 60,286–290.

    Google Scholar 

  30. Hamblen EC (1935) Results of preoperative administration of extract of pregnancy urine: study of ovaries and endometria in hyperplasia of endometrium following such administration. Endocrinology 19,169–178.

    Google Scholar 

  31. Hamblen EC (1939) Clinical evaluation of ovarian responses to gonadotropic therapy. Endocrinology 24,848–857.

    Google Scholar 

  32. Hamblen EC, Ross RA (1937) Responses of the human ovary to gonadotropic principles. Endocrinology 21,722–726.

    CAS  Google Scholar 

  33. Hamblen EC, Davis CD, Durham NC (1945) Treatment of hypo-ovarianism by the sequential and cyclic administration of equine and chorionic gonadotropins — so-called one-two cylic gonadotropic therapy summary of 5 years’ results. Am J Obstet Gynecol 50: 137–146

    Google Scholar 

  34. Howles CM (1996) Genetic engineering of human FSH (Gonal-F). Hum Reprod Update 2,172–191.

    Article  PubMed  CAS  Google Scholar 

  35. Hugues J-N, Barlow DH, Rosenwaks Z et al. (2003) Improvement in consistency of response to ovarian stimulation with recombinant human follicle stimulating hormone resulting from a new method for calibrating the therapeutic preparation. Reprod Biomed Online 6,185–190.

    Article  PubMed  CAS  Google Scholar 

  36. nsler V, Rikover M, Lunenfeld B, Toledo R (1966) The influence of human plasma and a synthetic plasma expander on the effect of human menopausal gonadotropin in female mice. J Endocrinol 36,211–212.

    Article  Google Scholar 

  37. Keene JL, Matzuk MM, Otani T, Fauser BCJM, Galway AB, Hsueh AJW, Boime I (1989) Expression of biologically active human follitropin in Chinese hamster ovary Cells. J Biol Chem 264,4769–4774.

    PubMed  CAS  Google Scholar 

  38. Lunenfeld B, Menzi A, Volet B (1960) Clinical effects of human postmenopausal gonadotrophin. In Fuchs F (ed) Advance Abstracts of Short Communications, First International Congress of Endocrinology. Copenhagen, 587 pp.

    Google Scholar 

  39. Lunenfeld B (1961) General discussion, P 383. In Albert A (ed) Charles C Thomas, Springfield, Illinois, USA, pp 53260–53269.

    Google Scholar 

  40. Lunenfeld B, Rabau E, Rumney G, Winkelsberg G (1961a) The responsiveness of the human ovary to gonadotrophin (Hypophsis III). Proc Third World Congress Gynecology and Obstetrics, Vienna, 1,220.

    Google Scholar 

  41. Lunenfeld B, Givol D, Sela M (1961b) Immunologic properties of urinary preparations of human menopausal gonadotropins, with special reference to Pergonal. J Clin Endocr Metab 21,478.

    CAS  Google Scholar 

  42. Lunenfeld B, Sulimovici S, Rabau E (1962a) Les éffets des gonadotrophins urinaires des femmes menopausées sur l’ovaire humain. CR Soc Franc Gynecol 32,291.

    Google Scholar 

  43. Lunenfeld B, Sulimovici S, Rabau E, Eshkol A (1962b) L’induction de l’ovulation dans les amenorrheas hypophysaires par un traitement combine de gonadotrophins urinaires menopausiques et de gonadotrophins chorioniques. CR Soc Franc Gynecol 32,346.

    Google Scholar 

  44. Lunenfeld B (1963) Treatment of anovulation by human gonadotrophins. J Int Fedn Gynecol Obstet 1,153.

    Google Scholar 

  45. Lunenfeld B (1967) Methods for assay for FSH. In Bell T and Loraine JA (eds) Recent Research on Gonadotrophic Hormones. E & S Livingstone, Edinburgh, p5.

    Google Scholar 

  46. Lunenfeld B, Donini P (1966) Historic aspects of gonadotropins in induction of ovulation. In Greenblatt RB (ed) Ovulation, JB Lippincott Co, USA, pp 105–117.

    Google Scholar 

  47. Maddock WO, Leach RB, Tokuyama I, Paulsen A, Roy WR (1956) Effects of Hog Pituitary Follicle stimulating hormone in women-antihormone formation and inhibition of ovarian function. J Clin Endcrinol Metab 16,433–448.

    CAS  Google Scholar 

  48. Mannaerts (2004) Personal communication

    Google Scholar 

  49. Mazer C, Ravetz E (1941) The effect of combined administration of chorionic gonadotropin and the pituitary synergist on the human ovary. Am J Obstet Gynaecol 41,474–588.

    CAS  Google Scholar 

  50. Netter A (1959) Activité en gynecologie d’un extrait gonadotrope d’origine hypophysaire. CR Soc Franc Gynecol 29,384–390.

    CAS  Google Scholar 

  51. Olijve W, de Boer W, Mulders JW, van Wezenbeek PM (1996) Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon). Mol Hum Reprod 2(5),371–382.

    Article  PubMed  CAS  Google Scholar 

  52. Ostergaard E (1942) Antigonadotrophic Substances. Ejnar Munksgaard, Copenhagen.

    Google Scholar 

  53. Out HJ, Mannaerts BMJL, Driessen SGA, Coelingh Bennink H (1995) A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle-stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization. Hum Reprod 10,2534–2540.

    PubMed  CAS  Google Scholar 

  54. Palmer R, Dorangeon P (1962) Les gonadotrophines dans les traitements de la stérilité féminine. CR Soc Franc Gynecol 32,407–415.

    Google Scholar 

  55. Rabinovici J, Blankstein J, Goldman B, Rudak E, Dor Y, Pariente C, Geier A, Lunenfeld B, Mashiach S (1989) In vitro fertilization and primary embryonic cleavage are possible in 17a-hydroxylase deficiency despite extremely low intrafollicular 17-estradiol. J Clin Endocrinol Metab 68, 693–697.

    PubMed  CAS  Google Scholar 

  56. Rathnam P, Saxena B (1975) Primary amino acid sequence of folliclestimulating hormone from human pituitary glands I alpha subunit. J Biol Chem 250,6735–6746.

    PubMed  CAS  Google Scholar 

  57. Rosenberg E, Coleman J, Damani M, Garcia CR (1962) Clinical effect of post menopausal gonadotropin. J Clin Endocrinol Metab 23,181–189.

    Article  Google Scholar 

  58. Rydberg E, Madsen V (1949) The treatment of functional sterility with gonadotropic hormones. Acta Obstet Gynecol Scand 19,222–246.

    Google Scholar 

  59. Rydberg E, Ostergaard E (1939) The effect of gonadotropic hormone treatment in cases of amenorrhoea. Acta Obstet Gynecol Scand 19, 222–246.

    Article  Google Scholar 

  60. Saxena BB, Rathnam P (1976) Amino acid sequence of the beta subunit of follicle-stimulating hormone from human pituitary glands. J Biol Chem 251,993–1005.

    PubMed  CAS  Google Scholar 

  61. SCRIP (2003) Metrodin HP withdrawn in the UK. Scrip World Pharmaceutical News (a PJB publication.) Vol 2824, 18.

    Google Scholar 

  62. Seegar-Jones GE, Gey GO, Ghisletta M (1943) Hormone production by placental cells maintained in continuous culture. Bull John Hopkins Hosp 72,26–38.

    Google Scholar 

  63. Shaked GM, Shaked Y, Kariv-Inbal Z, Halimi M, Avraham I, Gabizon R (2001) A protease-resistant Prion protein isoform is present in urine of animals and humans affected with prion diseases. J Biol Chem 276,31479–31482.

    Article  PubMed  CAS  Google Scholar 

  64. Smith PE (1926) Hastening of development of female genital system by daily hemoplastic pituitary transplants. Proc Soc Exp Biol Med 24, 1311–1333.

    Google Scholar 

  65. Smith PE (1927) The disabilities caused by hypophysectomy and their repair. J Am Med Assoc 88,158–161.

    CAS  Google Scholar 

  66. Smith PE, Engle ET (1927) Experimental evidence of the role of anterior pituitary in development and regulation of gonads. Am J Anat 40,159.

    Article  Google Scholar 

  67. Steelman SL, Pohley FM (1953) Assay of the follicle stimulating hormone based on the augmentation with human chorionic gonadotropin. Endocrinology 543,604–616.

    Google Scholar 

  68. Swissmedic letter (2003) TSE risk of medicines manufactured from human urine, foreseen measures to ensure medical safety, December 15, 2003.

    Google Scholar 

  69. Twombly GH (1936) Studies on the nature of antigonadotropic substances. Endocrinology 20,311–317.

    CAS  Google Scholar 

  70. Vesell M (1938) Cyclic treatment of a case of secondary amenorrhea of ten years duration. Am J Obstet Gynecol 35,1067–1072.

    Google Scholar 

  71. Vidal L (1959) Dictionaire des Specialtes Pharmaceutiques. In Office de Vulgarisation Pharmaceutique. Paris, 696 pp.

    Google Scholar 

  72. Wilkins L (1953) The need for an inhibitor of gonadotropin. J Clin Endcrinol Metab 13,739.

    Article  CAS  Google Scholar 

  73. Zondek B (1926) über die Funktion des Ovariums. Zeitschr Geburtsh Gynäkol 90,327.

    Google Scholar 

  74. Zondek B (1929) Weitere Untersuchungen zur Darstellung. Biologie und Klinik des Hypophysenvorderlappen-hormons (Prolan). Zentralbl Gynäkol 14,834–848.

    Google Scholar 

  75. Zondek B (1930) über die Hormone des Hypophysenvorderlappens. Klin Wochenschrift 9,245–248.

    Article  CAS  Google Scholar 

  76. Zondek B, Sulman F (1942) The Antigonadotropic Factor. Williams and Wilkins, Baltimore, pp 1–185.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Life Sciences, Bar-Ilan University, 7 Rva Ashi St., Ramat Gan 52900, 69395, Tel-Aviv, Israel

    B. Lunenfeld (Prof. M.D.)

  2. Zentrum für Gynäkologie, Endokrinologie u. Reproduktionsmedizin, Ostpassage 9, 30853, Hannover-Langenhagen

    K. Bühler (Dr. med.)

Authors
  1. B. Lunenfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Bühler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Lunenfeld, B., Bühler, K. (2007). Geschichte der Gonadotropintherapie. In: Das Deutsche IVF-Register 1996–2006. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-49928-2_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-49928-2_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-37324-7

  • Online ISBN: 978-3-540-49928-2

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation